PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Entacapone - Parkinson's disease
PAD Profile : Entacapone - Parkinson's disease
Keywords :
Parkinsons disease, PD, COMT inhibitors, catechol-o-methyltransferase inhibitors
Brand Names Include :
Comtess
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
COMT inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.
- Entacapone is the locally agreed 1st-choice COMT inhibitor (BLUE no information sheet)
- Opicapone is the locally agreed 2nd-choice COMT inhibitor (BLUE no information sheet)
- Tolcapone is the locally agreed 3rd-choice COMT inhiitor (AMBER shared care)
Initiation is to be carried out in in secondary care and prescribed by a specialist for a minimum of 2 months, doses stabilised and response to treatment reviewed prior to any transfer request to primary care.
Modifications to therapy should only be carried out on specialist advice.
Prescribers are reminded to prescribe generically and not by brand.
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism